Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bear Stearns Healthcare Conference In Brief

This article was originally published in The Gray Sheet

Executive Summary

Medtronic: Purchase of rapid-exchange stent-delivery technology from Johnson & Johnson is possible if the Federal Trade Commission requires J&J to sell the technology before completing its acquisition of Guidant. "Would we be interested? Yes...for the right price," Medtronic CFO Gary Ellis acknowledged at the Bear Stearns Healthcare Conference in New York Sept. 12. As conditions of approval for the acquisition, the European Commission and Canadian Competition Bureau are already requiring J&J to divest some businesses in their respective markets (1"The Gray Sheet" Sept. 5, 2005, In Brief). FTC is expected to rule on the proposed acquisition in October...

You may also be interested in...



J&J/Guidant Will Share RX Stent Delivery With Abbott If Guidant Deal Closes

Abbott could be a strong player in the drug-eluting stent market by 2007 if the J&J/Guidant merger is completed as required by FTC

J&J divests guidewires In Canada

Johnson & Johnson/Cordis will sell its steerable guidewire business in Canada in response to concerns raised by the Canadian Competition Bureau (CCB) in its review of the company's proposed $24 bil. acquisition of Guidant, J&J announced Sept. 2. CCB is not formally requiring J&J to divest the business as a condition of approving the merger, but said that it is concerned the merger will make the steerable guidewire market uncompetitive and that it will continue to monitor the markets affected by the merger for three years, as provided under Canada's Competition Act. The firm was also asked to divest certain European businesses as a condition of EC approval of the acquisition. The U.S. Federal Trade Commission's decision is expected in October (1"The Gray Sheet" Aug. 29, 2005, p. 13)...

Ocular Sciences Acquisition Puts Ciba, J&J/Vistakon In Cooper’s Sights

Cooper Companies' planned Ocular Sciences purchase positions the firm to achieve $1 bil. in annual contact lens sales by 2007, according to CEO Thomas Bender

UsernamePublicRestriction

Register

PS100968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel